Table 1. Sociodemographic and clinical characteristics of study participants (mean ± standard deviation).
| Variables | All patients (76) |
Fallers (44) |
Non-fallers (32) |
P-value |
|---|---|---|---|---|
| Sociodemographic characteristics | ||||
| Sex (% M) | 53.9 | 52.3 | 58.1 | 0.620 |
| Age (years) | 61.1±14 | 59.9±13.2 | 62.3±15.2 | 0.482 |
| Weight (Kg) | 79.7±18.3 | 77.4±18.8 | 83.1±17.7 | 0.117 |
| Height (cm) | 165.8±8.7 | 166.4±9.7 | 165.3±7.2 | 0.595 |
| BMI (Kg * m-2) | 29±6.3 | 28±6.7 | 30.3±5.6 | 0.131 |
| Clinical history | ||||
| Dialysis vintage (days) | 726±716 | 755±777 | 666±633 | 0.780 |
| CCI (score) | 5.2±2.3 | 5.2±2.1 | 5.2±2.6 | 0.841 |
| Primary renal disease (%) | ||||
| Diabetic nephropathy | 26.7 | 34.9 | 12.9 | 0.033 |
| Glomerulonephritis | 18.7 | 18.6 | 19.4 | 0.935 |
| Polycystic kidney | 12 | 2.3 | 25.8 | 0.002 |
| Renovascular or hypertensive | 8 | 4.7 | 12.9 | 0.199 |
| Other | 18.7 | 20.9 | 16.1 | 0.603 |
| Uncertain aetiology | 17.3 | 18.6 | 12.9 | 0.512 |
| Type of vascular access (%) | ||||
| Arteriovenous fistula | 66.2 | 62.8 | 71 | 0.463 |
| Central-venous | 33.8 | 37.2 | 29 | 0.463 |
| Inter-dialytic weight gain (Kg) | 1.5±1.3 | 1.6±1.4 | 1.5±1.2 | 0.849 |
| Prescribed medications | ||||
| Medications (n°) | 11.8±3.7 | 12.3±3.8 | 11±3.7 | 0.106 |
| Beta blockers use (%) | 49.3 | 43.2 | 56.7 | 0.255 |
| ACE-inhibitors use (%) | 8 | 4.5 | 13.3 | 0.174 |
| Ca-channel blockers use (%) | 56 | 59.1 | 53.3 | 0.624 |
| AngII-receptor antagonists use (%) | 16 | 15.9 | 16.7 | 0.931 |
| Alpha blockers use (%) | 29.3 | 36.4 | 20 | 0.131 |
| Antihypertensive use (%) | 84 | 81.2 | 86.7 | 0.579 |
| >1 antihypertensive use (%) | 50 | 50 | 50 | 1.000 |
| Opiates use (%) | 20 | 15.9 | 26.7 | 0.258 |
| Antidepressants use (%) | 32 | 38.6 | 23.3 | 0.167 |
| Diuretics use (%) | 37.3 | 27.3 | 53.3 | 0.023 |
| Laboratory values | ||||
| Hb (g/dL) | 11.2±1.2 | 11.2±1.1 | 11.2±1.2 | 0.763 |
| CRP (mg/L) | 24.3±43.6 | 28.7±49.8 | 17.6±33.4 | 0.083 |
| Bicarbonate (mmol/L) | 21.2±3.2 | 21.4±3.3 | 20.8±3 | 0.455 |
| Na (mmol/L) | 139±2.8 | 138.7±3 | 139.4±2.5 | 0.728 |
| K (mmol/L) | 4.6±0.7 | 4.7±0.7 | 4.5±0.6 | 0.690 |
| Urea (mg/dL) | 16.3±5.1 | 16.2±5.9 | 16.4±4.1 | 0.859 |
| Phosphate (mmol/L) | 1.5±0.6 | 1.5±0.6 | 1.5±0.5 | 0.894 |
| PTH (ρmol/L) | 27.5±31.3 | 27.3±34.2 | 27.9±27.9 | 0.859 |
| Albumin (g/L) | 37.1±4.2 | 36.8±4.5 | 37.5±3.8 | 0.435 |
| Adjusted calcium (mmol/L) | 2.3±0.1 | 2.3±.01 | 2.4±0.1 | 0.983 |
| URR (%) | 71.2±6 | 71.9±6.5 | 70.1±5.1 | 0.205 |
| Kt/V | 1.4±0.3 | 1.4±0.3 | 1.3±0.2 | 0.167 |
| Creatinine (μmol/L) | 634.3±159.9 | 617.4±173.7 | 654.6±139.6 | 0.326 |
Abbreviations: BMI: body mass index; CCI: Charlson comorbidity index; ACE: angiotensin-converting enzyme; Ca: calcium; AngII: angiotensin II; Hb: hemoglobin; CRP: C-reactive protein; Na: sodium; K: potassium; PTH: parathyroid hormone; URR: urea reduction ratio.